Pharmaceuticals

Transforming cannabinoid science into breakthrough therapies for billion-dollar markets. Our pharmaceutical pipeline leverages EU-GMP manufacturing excellence, proprietary formulations, and deep regulatory expertise to advance high-value therapeutics targeting massive unmet medical needs, creating sustainable competitive advantages that drive API demand while generating high-margin licensing revenue.

Proven Pipeline. $50+ Billion Market Transformation.

Our portfolio strategically targets the highest-value opportunities where regulatory pathways, clinical validation, and market timing converge. Opioid Use Disorder ($8.4B market), Refractory Epilepsy (first globally market-authorized CBD API), Glaucoma ($100M+ peak revenue), and Insomnia (Australia market exclusivity). Each program reinforces our API platform while creating multiple paths to extraordinary returns.

Our pharmaceutical programs create a powerful value flywheel: driving API demand, securing exclusive partnerships, and generating high-margin licensing revenue across our integrated platform.

Projected Value Distribution

Lead Clinical Programs

Multiple Catalysts Across Billion-Dollar Markets

Opioid Use Disorder

NIH-funded Phase 3 trial targeting >$450M peak revenue in $8.4B market by 2033, with Mount Sinai partnership providing full regulatory rights and minimal development risk

Refractory Epilepsy

Under ANVISA review in Brazil, positioned to become first globally market-authorized CBD API for pharmaceutical use, creating regulatory precedent and immediate global expansion pathways

Glaucoma

Extended-release methazolamide advancing under FDA Special Protocol Assessment with Effcon partnership, targeting >$100M peak revenue with expansion potential across neurological indications

Insomnia

Australia's first Schedule 3 CBD product launching 2027, five-year market exclusivity in A$125M annual opportunity with patent-protected BioAbsorb® formulation demonstrating clinical efficacy

Clinical Pipeline Architecture​​

Three Strategic Horizons

Horizon 1:

Near-Term Revenue Catalysts (12-18 Months)

Leveraging existing clinical data and regulatory pathways for immediate market access.

Horizon 2:

Mid-Term Growth Engines (18-40 Months)

Late-stage clinical assets with regulatory filings in progress.

Horizon 3:

Long-Term Innovation Programs

High-upside biotech opportunities targeting massive unmet needs.

The Future of Medicine is Being Written Here

Brains Bio's pharmaceutical division represents more than drug development, it's the systematic transformation of cannabinoid science into life-changing therapies that address humanity's most pressing medical needs. With multiple programs advancing toward commercial milestones, regulatory catalysts creating near-term value, and a platform designed for sustained innovation, we're not just participating in the future of medicine.

In addition to drug development, the division is powered by Brains Bio’s diversified cannabinoid ingredient platform, comprising four APIs, four nutraceutical ingredients, and drug intermediate products. This platform ensures vertical integration and supply security while positioning clinical programs as growth engines that pull through demand for Brains’ APIs. By linking every development asset back to the API platform, Brains demonstrates clear synergy between its science and its core business, creating sustainable value across both internal programs and external partnerships.

Transforming Cannabinoid Medicine with AI

Brains Bioceutical is pioneering cannabinoid precision medicine using advanced AI tools to unlock novel therapies for central nervous system disorders. The BrainsAI™ ecosystem combines real-world patient data, personalized dosing insights, and predictive drug discovery.